Enterprise Tuesday – Scaling with innovative finance

One of the things the recent pandemic has taught us is the importance of investing in science and technology that can change our future world and taking present day action to increase our chances of getting there early. How can we demystify the opportunities to invest in new innovators who are demonstrating the art of the possible and help them unlock the potential in their idea?

What format can these opportunities take from working with established funding sources to change their perspective to forming alternative funding models with new and existing partners? Ready to push your entrepreneurial potential and meet likeminded others?

Doors open at 18:00 and we encourage you to arrive promptly as places are limited. We will allocate seats on a first-come, first-served basis.

Chaired by: Hanadi Jabado DL, Managing Partner, Sana Capital

Guest speakers:

• Mark Bloomfield, Founder, Turbulence​
• Amelia Armour, Partner, Amadeus Capital Partners​
• Dr Christine Martin, Head of Seed Funds Cambridge Enterprise​

If you are unable to attend this session after you have registered, we ask that you to cancel your seat as soon as possible to free it up for someone else.

About Enterprise Tuesday

Enterprise Tuesday is a popular series for local entrepreneurs. The talks are open to everyone but prior registration is essential. We strongly recommend registering early to ensure you get a seat. There is limited seating capacity of 80 places for each talk.

Have a question? Please email the team at [email protected].

Find out more about future guest speakers and topics

Speakers bios

Hanadi Jabado DL, Managing Partner, Sana Capital

Hanadi is passionate about entrepreneurship and innovation. She supports early-stage businesses across a range of sectors with a focus on HealthTech and Deep-Tech. She has a particular interest in TechBio and Data-driven startups. Her ability to act as a technology translator and to align vision and strategy with operational constraints are key to her high success rate. Hanadi’s experience in developing innovation clusters is globally recognised. She has helped set up entrepreneurial ecosystems in the Middle East, Russia and China. Her work to support entrepreneurs earned her recognition as one of the Maserati100 in 2016, and as top 20 Asians Tech Pioneers in 2020.
In 2012, Hanadi was the inspiration and driving force behind the creation of Accelerate Cambridge, which enhanced the Cambridge Judge Business School’s contribution to the Cambridge entrepreneurial cluster by providing help, nurture, and support to innovators and entrepreneurs in the cluster. Through her work at Accelerate Cambridge, Hanadi has supported the creation and scale-up of over 180 early-stage ventures, building a portfolio of an estimated collective value of £1.5bn and over £300m of risk capital raised.

In early 2016 Hanadi was appointed Executive Director of the Entrepreneurship Centre at Cambridge Judge. Her work in Cambridge is already enabling a unique platform for entrepreneurship research on the underpinning factors of entrepreneurial success from both the entrepreneur’s and the early investor’s perspectives.

Since January 2019, Hanadi has centred her work around the investment needs of early-stage ventures and more specifically, the funding gap in the UK for ambitious life-sciences and biotech businesses. This led to the creation of CMS Ventures, and Hanadi’s appointment as its managing director. CMS Ventures is an early-stage investor based in Cambridge investing in Biotech & Life Sciences start-ups in the UK with a focus on the 4Ds (Drugs, Devices, Diagnostics, and Digital) and privileged access to international markets, in particular China.

Hanadi serves as a Deputy Lieutenant of Cambridgeshire. In addition, Hanadi is an independent external member of the Innovate UK Innovation Loans Credit Committee, sits on the LIF steering committee at the Royal Academy of Engineering, and is a President Fellow at Murray Edwards College.

Hanadi is currently working on the launch of a UK-based HealthTech early-stage fund, focusing on scaling the work of ambitious founders wanting to positively impact the world.

Born in Lebanon and raised in France, she is fluent in English, French and Arabic while speaking another four languages. Currently living in Cambridge with her four children, you can catch Hanadi walking her two eccentric dogs or sculling, coxing or rowing on the river.

Mark Bloomfield, Founder, Turbulence

Dr. Mark Bloomfield, Founder of Turbulence, helps organisations transform to enable resilience growth. As a Cambridge Judge Business School Fellow, he teaches innovation & experimentation to global senior leaders. Previously, Mark directed Commercial Transformation at Global Media & Entertainment for 10+ years embedding data science and innovation capabilities. He also served as Head of Operations Research at Thomas Cook Group. Mark holds a PhD in Aerospace Engineering from the University of Bristol with Airbus and collaborates with start-ups across sectors as an advisor.

Amelia Armour, Partner, Amadeus Capital Partners

Amelia joined Amadeus Capital Partners in 2009 and is a Partner in the Early Stage Fund. Her current investment focus is on autonomous systems, AI and machine learning, cloud computing and novel materials. She is a Director on several boards including Xampla, who have developed a plant-based material to replace single-use plastics; iPronics who are building the world’s first programmable photonic processor; Riverlane a developer of the operating system for error corrected quantum computers and SLAMcore, a spin-out from Imperial College, developing spatial intelligence for autonomous robotics and drones. Amelia is also an active board observer at other companies including enterprise voice assistant company PolyAI and Graphcore, the developer of the Intelligence Processing Unit for next generation machine intelligence. Prior to Amadeus, she worked at Barclays Investment Bank as a manager in the structured capital markets team with responsibility for running a portfolio of multi-jurisdiction transactions. Amelia has also worked in structured finance at the Commonwealth Bank of Australia. She qualified as a chartered accountant with Deloitte in London in the corporate tax department.

Dr Christine Martin, Head of Seed Funds Cambridge Enterprise

Christine oversees investment activities at Cambridge Enterprise. With expertise in Life Science investment, Christine has a focus on drug discovery with a broad portfolio of technologies, including University of Cambridge spin-outs Carrick, STORM, Z-factor, PhoreMost, Qkine, and PolyProX. Christine was featured in BioBeat’s 50 Movers and Shakers in BioBusiness 2018.